Complications after percutaneous radiofrequency ablation of renal tumors

Alon Z. Weizer, Ganesh V. Raj, Martin O'Connell, Cary N. Robertson, Rendon C. Nelson, Thomas J. Polascik

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Objectives. To evaluate our experience with percutaneous radiofrequency ablation (pRFA) to determine common characteristics of patients with complications, to elucidate possible relative contraindications to therapy. Methods. Medical records of all patients undergoing pRFA were reviewed for demographic data, medical and surgical history, indication, tumor characteristics, and treatment information (complications and management). The group of patients with complications was analyzed for common characteristics. Results. From January 2000 to September 2003, 24 patients (mean age 61 years, 5:1 male/female) with 32 renal tumors were treated with pRFA. Indications for pRFA included prior renal surgery and/or chronic renal insufficiency, significant medical disease, patient choice, von Hippel-Lindau disease, and treatment of a metastasis. Average pretreatment tumor size was 2.4 cm (range 0.5-8.6 cm). Of the 5 patients experiencing complications from pRFA treatment, 2 developed perinephric hematomas, 1 had a persistent urinoma and proximal ureteral stricture, and 2 had colonic injuries. Among patients with complications, 3 of 5 had undergone prior partial nephrectomy on the pRFA-treated kidney. Two of four patients treated for multiple tumors and 57% of patients (4 of 7) with anteriorly located tumors experienced complications. Conclusions. Early experience with pRFA for renal tumor seems promising, but patient selection criteria are evolving. On the basis of our limited experience, we recommend caution when using renal pRFA in patients with prior partial nephrectomy, multiple tumors treated in the same setting, and tumors located anteriorly or centrally. Further clinical experience will help establish guidelines for the use of this powerful technology in the management of renal tumors.

Original languageEnglish (US)
Pages (from-to)1176-1180
Number of pages5
JournalUrology
Volume66
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Kidney
Neoplasms
Nephrectomy
Patient Selection
Urinoma
von Hippel-Lindau Disease
Information Management
Therapeutics
Chronic Renal Insufficiency
Hematoma
Medical Records
Pathologic Constriction
History
Demography
Guidelines
Neoplasm Metastasis
Technology
Wounds and Injuries

ASJC Scopus subject areas

  • Urology

Cite this

Weizer, A. Z., Raj, G. V., O'Connell, M., Robertson, C. N., Nelson, R. C., & Polascik, T. J. (2005). Complications after percutaneous radiofrequency ablation of renal tumors. Urology, 66(6), 1176-1180. https://doi.org/10.1016/j.urology.2005.06.125

Complications after percutaneous radiofrequency ablation of renal tumors. / Weizer, Alon Z.; Raj, Ganesh V.; O'Connell, Martin; Robertson, Cary N.; Nelson, Rendon C.; Polascik, Thomas J.

In: Urology, Vol. 66, No. 6, 12.2005, p. 1176-1180.

Research output: Contribution to journalArticle

Weizer, AZ, Raj, GV, O'Connell, M, Robertson, CN, Nelson, RC & Polascik, TJ 2005, 'Complications after percutaneous radiofrequency ablation of renal tumors', Urology, vol. 66, no. 6, pp. 1176-1180. https://doi.org/10.1016/j.urology.2005.06.125
Weizer AZ, Raj GV, O'Connell M, Robertson CN, Nelson RC, Polascik TJ. Complications after percutaneous radiofrequency ablation of renal tumors. Urology. 2005 Dec;66(6):1176-1180. https://doi.org/10.1016/j.urology.2005.06.125
Weizer, Alon Z. ; Raj, Ganesh V. ; O'Connell, Martin ; Robertson, Cary N. ; Nelson, Rendon C. ; Polascik, Thomas J. / Complications after percutaneous radiofrequency ablation of renal tumors. In: Urology. 2005 ; Vol. 66, No. 6. pp. 1176-1180.
@article{8571ab297d53446f8c6b739f86ac182b,
title = "Complications after percutaneous radiofrequency ablation of renal tumors",
abstract = "Objectives. To evaluate our experience with percutaneous radiofrequency ablation (pRFA) to determine common characteristics of patients with complications, to elucidate possible relative contraindications to therapy. Methods. Medical records of all patients undergoing pRFA were reviewed for demographic data, medical and surgical history, indication, tumor characteristics, and treatment information (complications and management). The group of patients with complications was analyzed for common characteristics. Results. From January 2000 to September 2003, 24 patients (mean age 61 years, 5:1 male/female) with 32 renal tumors were treated with pRFA. Indications for pRFA included prior renal surgery and/or chronic renal insufficiency, significant medical disease, patient choice, von Hippel-Lindau disease, and treatment of a metastasis. Average pretreatment tumor size was 2.4 cm (range 0.5-8.6 cm). Of the 5 patients experiencing complications from pRFA treatment, 2 developed perinephric hematomas, 1 had a persistent urinoma and proximal ureteral stricture, and 2 had colonic injuries. Among patients with complications, 3 of 5 had undergone prior partial nephrectomy on the pRFA-treated kidney. Two of four patients treated for multiple tumors and 57{\%} of patients (4 of 7) with anteriorly located tumors experienced complications. Conclusions. Early experience with pRFA for renal tumor seems promising, but patient selection criteria are evolving. On the basis of our limited experience, we recommend caution when using renal pRFA in patients with prior partial nephrectomy, multiple tumors treated in the same setting, and tumors located anteriorly or centrally. Further clinical experience will help establish guidelines for the use of this powerful technology in the management of renal tumors.",
author = "Weizer, {Alon Z.} and Raj, {Ganesh V.} and Martin O'Connell and Robertson, {Cary N.} and Nelson, {Rendon C.} and Polascik, {Thomas J.}",
year = "2005",
month = "12",
doi = "10.1016/j.urology.2005.06.125",
language = "English (US)",
volume = "66",
pages = "1176--1180",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Complications after percutaneous radiofrequency ablation of renal tumors

AU - Weizer, Alon Z.

AU - Raj, Ganesh V.

AU - O'Connell, Martin

AU - Robertson, Cary N.

AU - Nelson, Rendon C.

AU - Polascik, Thomas J.

PY - 2005/12

Y1 - 2005/12

N2 - Objectives. To evaluate our experience with percutaneous radiofrequency ablation (pRFA) to determine common characteristics of patients with complications, to elucidate possible relative contraindications to therapy. Methods. Medical records of all patients undergoing pRFA were reviewed for demographic data, medical and surgical history, indication, tumor characteristics, and treatment information (complications and management). The group of patients with complications was analyzed for common characteristics. Results. From January 2000 to September 2003, 24 patients (mean age 61 years, 5:1 male/female) with 32 renal tumors were treated with pRFA. Indications for pRFA included prior renal surgery and/or chronic renal insufficiency, significant medical disease, patient choice, von Hippel-Lindau disease, and treatment of a metastasis. Average pretreatment tumor size was 2.4 cm (range 0.5-8.6 cm). Of the 5 patients experiencing complications from pRFA treatment, 2 developed perinephric hematomas, 1 had a persistent urinoma and proximal ureteral stricture, and 2 had colonic injuries. Among patients with complications, 3 of 5 had undergone prior partial nephrectomy on the pRFA-treated kidney. Two of four patients treated for multiple tumors and 57% of patients (4 of 7) with anteriorly located tumors experienced complications. Conclusions. Early experience with pRFA for renal tumor seems promising, but patient selection criteria are evolving. On the basis of our limited experience, we recommend caution when using renal pRFA in patients with prior partial nephrectomy, multiple tumors treated in the same setting, and tumors located anteriorly or centrally. Further clinical experience will help establish guidelines for the use of this powerful technology in the management of renal tumors.

AB - Objectives. To evaluate our experience with percutaneous radiofrequency ablation (pRFA) to determine common characteristics of patients with complications, to elucidate possible relative contraindications to therapy. Methods. Medical records of all patients undergoing pRFA were reviewed for demographic data, medical and surgical history, indication, tumor characteristics, and treatment information (complications and management). The group of patients with complications was analyzed for common characteristics. Results. From January 2000 to September 2003, 24 patients (mean age 61 years, 5:1 male/female) with 32 renal tumors were treated with pRFA. Indications for pRFA included prior renal surgery and/or chronic renal insufficiency, significant medical disease, patient choice, von Hippel-Lindau disease, and treatment of a metastasis. Average pretreatment tumor size was 2.4 cm (range 0.5-8.6 cm). Of the 5 patients experiencing complications from pRFA treatment, 2 developed perinephric hematomas, 1 had a persistent urinoma and proximal ureteral stricture, and 2 had colonic injuries. Among patients with complications, 3 of 5 had undergone prior partial nephrectomy on the pRFA-treated kidney. Two of four patients treated for multiple tumors and 57% of patients (4 of 7) with anteriorly located tumors experienced complications. Conclusions. Early experience with pRFA for renal tumor seems promising, but patient selection criteria are evolving. On the basis of our limited experience, we recommend caution when using renal pRFA in patients with prior partial nephrectomy, multiple tumors treated in the same setting, and tumors located anteriorly or centrally. Further clinical experience will help establish guidelines for the use of this powerful technology in the management of renal tumors.

UR - http://www.scopus.com/inward/record.url?scp=29144476512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144476512&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.06.125

DO - 10.1016/j.urology.2005.06.125

M3 - Article

C2 - 16360436

AN - SCOPUS:29144476512

VL - 66

SP - 1176

EP - 1180

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -